Sofosbuvir plus simeprevir plus /- ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort

Christophe Moreno (1) , Moutaz Derbala , Eric Nguyen-Khac (2) , Mohamed A. Babatin , Isabelle Rosa (3) , Mohamed Alzaabi , Bertrand Hanslik (4) , Alessandra Mangia (5) , Tarik Asselah (6) , Peter Buggisch (7) , Stefan Mauss (8) , Thomas Serste (9) , Jean Delwaide , Saad R. Alkaabi , Alexandre Pariente (10) , Andre Jean Remy , Abdullah S. Alghamdi , Jean-Francois Cadranel (11) , Syed A. Mohiuddin , Delphine Degre (9, 12)

1 ULB - Hôpital Erasme [Bruxelles]
2 GRAP - Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247
3 CHI Créteil
4 CHU - Centre Hospitalier Universitaire [Grenoble]
5 IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Casa Sollievo della Sofferenza [San Giovanni Rotondo]
6 Service d’Hépatologie [Hôpital Beaujon]
7 Institute for Interdisciplinary Medicine Hamburg
8 Department of Gastroenterology, Hepatology and Infectiology [Düsseldorf]
9 Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology [Brussels, Belgium]
10 Centre hospitalier de Pau
11 Service d'hépato-gastroentérologie
12 Laboratory of Experimental Gastroenterology [Brussels, Belgium]

Domaines: Sciences du Vivant [q-bio]

Christophe Moreno, Moutaz Derbala, Eric Nguyen-Khac, Mohamed A. Babatin, Isabelle Rosa, et al.. Sofosbuvir plus simeprevir plus /- ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort. Hepatology, 2016, 64 (1), pp.989A. ⟨hal-03590931⟩